$GALT
GALECTIN THERAPEUTICS INC

2024 Q4 Form 10-Q Financial Statement

#000114036124046726 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.471M
YoY Change 2.87%
% of Gross Profit
Research & Development $7.595M
YoY Change -1.77%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.066M
YoY Change -1.09%
Operating Profit -$9.066M
YoY Change -1.09%
Interest Expense -$2.154M
YoY Change -357.96%
% of Operating Profit
Other Income/Expense, Net -$2.154M
YoY Change 70.68%
Pretax Income -$11.22M
YoY Change 7.57%
Income Tax
% Of Pretax Income
Net Earnings -$11.22M
YoY Change 7.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 62.76M 62.28M
Diluted Shares Outstanding 62.28M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.06M
YoY Change 32.91%
Cash & Equivalents $27.06M
Short-Term Investments
Other Short-Term Assets $1.606M
YoY Change 28.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.67M
YoY Change 32.65%
LONG-TERM ASSETS
Property, Plant & Equipment $26.00K
YoY Change -56.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $306.0K
YoY Change -44.57%
Total Long-Term Assets $306.0K
YoY Change -44.57%
TOTAL ASSETS
Total Short-Term Assets $28.67M
Total Long-Term Assets $306.0K
Total Assets $28.97M
YoY Change 30.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.795M
YoY Change 4.25%
Accrued Expenses $11.59M
YoY Change 47.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $10.52M
YoY Change
Total Short-Term Liabilities $25.26M
YoY Change 140.05%
LONG-TERM LIABILITIES
Long-Term Debt $94.04M
YoY Change 53.8%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.26M
Total Long-Term Liabilities $0.00
Total Liabilities $121.5M
YoY Change 66.29%
SHAREHOLDERS EQUITY
Retained Earnings -$389.5M
YoY Change 13.14%
Common Stock $62.00K
YoY Change 1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$94.20M
YoY Change
Total Liabilities & Shareholders Equity $28.97M
YoY Change 30.72%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$11.22M
YoY Change 7.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.538M
YoY Change 11.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00M
YoY Change -0.3%
NET CHANGE
Cash From Operating Activities -8.538M
Cash From Investing Activities
Cash From Financing Activities 10.00M
Net Change In Cash 1.462M
YoY Change -39.08%
FREE CASH FLOW
Cash From Operating Activities -$8.538M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3562325
dei Entity Address Address Line1
EntityAddressAddressLine1
4960 Peachtree Industrial Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 240
dei Entity Address City Or Town
EntityAddressCityOrTown
Norcross
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30071
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62761825
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31791
dei Entity Registrant Name
EntityRegistrantName
GALECTIN THERAPEUTICS INC.
dei City Area Code
CityAreaCode
678
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27060000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25660000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1606000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2050000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
28666000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
27710000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
306000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q3 us-gaap Assets
Assets
28972000
CY2023Q4 us-gaap Assets
Assets
28200000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2795000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6431000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11586000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9182000
CY2024Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
63000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25258000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2024Q3 us-gaap Liabilities
Liabilities
121453000
CY2023Q4 us-gaap Liabilities
Liabilities
88441000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000
CY2024Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
176
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
176
CY2024Q3 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
8124000
CY2024Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
1760000
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2023Q4 galt Undesignated Capital Stock Par Value
UndesignatedCapitalStockParValue
0.01
CY2024Q3 galt Undesignated Capital Stock Par Value
UndesignatedCapitalStockParValue
0.01
CY2024Q3 galt Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
20000000
CY2023Q4 galt Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
20000000
CY2024Q3 galt Undesignated Capital Stock Shares Designated
UndesignatedCapitalStockSharesDesignated
20000000
CY2023Q4 galt Undesignated Capital Stock Shares Designated
UndesignatedCapitalStockSharesDesignated
20000000
CY2024Q3 galt Undesignated Capital Stock Value
UndesignatedCapitalStockValue
0
CY2023Q4 galt Undesignated Capital Stock Value
UndesignatedCapitalStockValue
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1742500
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1742500
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1235000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1235000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1235000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1235000
CY2024Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1235000
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
500000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
500000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62308075
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62308075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61852914
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61852914
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
62000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
61000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
294776000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
291847000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-389542000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-354372000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-61964000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28972000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28200000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7595000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7732000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25462000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23902000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1471000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4543000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4609000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
9066000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
9166000
us-gaap Operating Expenses
OperatingExpenses
30005000
us-gaap Operating Expenses
OperatingExpenses
28511000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9066000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9166000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30005000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28511000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
62000
us-gaap Investment Income Interest
InvestmentIncomeInterest
254000
us-gaap Investment Income Interest
InvestmentIncomeInterest
156000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1494000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
835000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3815000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1945000
CY2024Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-753000
CY2023Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-489000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-1514000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-769000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2154000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1262000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5075000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2558000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11220000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10428000
us-gaap Net Income Loss
NetIncomeLoss
-35080000
us-gaap Net Income Loss
NetIncomeLoss
-31069000
CY2024Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
18000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-6000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
90000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
57000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11238000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14041000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35170000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62278000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62278000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59704000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59704000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62163000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62163000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59590000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59590000
us-gaap Net Income Loss
NetIncomeLoss
-35080000
us-gaap Net Income Loss
NetIncomeLoss
-31069000
us-gaap Share Based Compensation
ShareBasedCompensation
1857000
us-gaap Share Based Compensation
ShareBasedCompensation
1764000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
24000
us-gaap Paid In Kind Interest
PaidInKindInterest
748000
us-gaap Paid In Kind Interest
PaidInKindInterest
505000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1514000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
769000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-444000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-711000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1553000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2406000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3067000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1439000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28976000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28263000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
20000000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
376000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30376000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30033000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1400000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1770000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25660000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18592000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27060000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20362000
us-gaap Stock Issued1
StockIssued1
90000
us-gaap Stock Issued1
StockIssued1
57000
galt Reclassification Of Accrued Bonus To Additional Paid In Capital
ReclassificationOfAccruedBonusToAdditionalPaidInCapital
210000
galt Common Stock Purchase Warrants Issued In Connection With Related Party Line Of Credit
CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
845000
galt Common Stock Purchase Warrants Issued In Connection With Related Party Line Of Credit
CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit
477000
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">1. Basis of Presentation, Liquidity and Going Concern<br/> </div> <div style="display:none;"><br/></div> <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="display:none;"><br/></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.</div> <div style="display:none;"><br/></div> <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="display:none;"><br/></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of September 30, 2024 and the results of its operations for the three and nine months ended September 30, 2024 and 2023 and its cash flows for the nine months ended September 30, 2024 and 2023. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2023 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2023.</div> <div style="display:none;"><br/></div> <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="display:none;"><br/></div> <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-indent: 27pt;">The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2024, the company had $27,060,000 of unrestricted cash and cash equivalents available to fund future operations. In addition, on November 14, 2024, the Company entered into a second supplemental unsecured $6 million line of credit financing with its chairman, Richard E. Uihlein (see note 9). The Company believes there is sufficient cash to fund currently planned operations approximately through May 2025. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements. The ability of the Company to continue as a going concern is likely dependent on the results of its NAVIGATE clinical trial expected in December 2024 and its ability to raise capital; however, the Company’s cash position may not be sufficient to support its daily operations after May 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.</div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span> </div> <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.</div>
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001133416
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
galt Free Rent Period
FreeRentPeriod
P6M15D
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Local Phone Number
LocalPhoneNumber
620 -3186
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GALT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 galt Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Current
ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent
10518000
CY2023Q4 galt Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Current
ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent
0
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
359000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15676000
CY2024Q3 galt Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Non Current
ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
21094000
CY2023Q4 galt Convertible Note Payable And Accrued Interest Net Of Debt Discount Related Party Non Current
ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent
30902000
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2159000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1004000
CY2024Q3 galt Borrowing And Accrued Interest Under Line Of Credit Net Of Debt Discount Related Party Noncurrent
BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
72942000
CY2023Q4 galt Borrowing And Accrued Interest Under Line Of Credit Net Of Debt Discount Related Party Noncurrent
BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent
40839000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-94204000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
93000
CY2023Q3 galt Fair Value Adjustment Of Warrant
FairValueAdjustmentOfWarrant
3619000
galt Fair Value Adjustment Of Warrant
FairValueAdjustmentOfWarrant
3619000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34745000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10033000
galt Reclassification Of Accrued Bonus To Additional Paid In Capital
ReclassificationOfAccruedBonusToAdditionalPaidInCapital
0
galt Fair Value Adjustment Of Warrant
FairValueAdjustmentOfWarrant
3619000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
176
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1723000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-52850000
CY2023Q3 galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
39000
CY2023Q3 galt Temporary Equity Dividends
TemporaryEquityDividends
25000
CY2023Q3 galt Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
10033000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
516000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10428000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-52596000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-83870000
CY2024Q3 galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
37000
CY2024Q3 galt Temporary Equity Dividends
TemporaryEquityDividends
26000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
308000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
515000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11220000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-94204000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-33917000
galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
38000
galt Temporary Equity Dividends
TemporaryEquityDividends
24000
galt Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
10033000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
477000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1818000
us-gaap Net Income Loss
NetIncomeLoss
-31069000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-52596000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-61964000
galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
37000
galt Temporary Equity Dividends
TemporaryEquityDividends
26000
galt Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
376000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
845000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1556000
us-gaap Net Income Loss
NetIncomeLoss
-35080000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-94204000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27060000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
96000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
40000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1059000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1129000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
32000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46000
CY2024Q3 galt Accrued Research And Development Costs And Other Current
AccruedResearchAndDevelopmentCostsAndOtherCurrent
10399000
CY2023Q4 galt Accrued Research And Development Costs And Other Current
AccruedResearchAndDevelopmentCostsAndOtherCurrent
7967000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11586000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9182000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
515000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
586000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1342000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1856000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6333841
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1373000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49583
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
348750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.35
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7308508
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.35
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1154000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2475171
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1373000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0388
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0384
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
galt Vesting Percentage Of Restricted Stock Units
VestingPercentageOfRestrictedStockUnits
1
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y2M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49402846
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33232640
galt Contract Cancelation Notice Period
ContractCancelationNoticePeriod
P30D
galt Number Of Operating Leases
NumberOfOperatingLeases
1
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P38M
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
6000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
32000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
13000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
20000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
32000
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.11
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
galt-20240930_pre.xml Edgar Link unprocessable
0001140361-24-046726-index-headers.html Edgar Link pending
0001140361-24-046726-index.html Edgar Link pending
0001140361-24-046726.txt Edgar Link pending
0001140361-24-046726-xbrl.zip Edgar Link pending
ef20034540_10q.htm Edgar Link pending
ef20034540_ex10-1.htm Edgar Link pending
ef20034540_ex31-1.htm Edgar Link pending
ef20034540_ex31-2.htm Edgar Link pending
ef20034540_ex32-1.htm Edgar Link pending
ef20034540_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
galt-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
galt-20240930_cal.xml Edgar Link unprocessable
galt-20240930_def.xml Edgar Link unprocessable
galt-20240930_lab.xml Edgar Link unprocessable
ef20034540_10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending